A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours.

被引：43

作者：

Halford, Sarah E. R.

Jones, Paul

Wedge, Steve

Hirschberg, Sandra

Katugampola, Sidath

Veal, Gareth

Payne, Geoffrey

Bacon, Chris

Potter, Sarah

Griffin, Melanie

Chenard-Poirier, Maxime

Petrides, George

Holder, Graham

Keun, Hector C.

Banerji, Udai

Plummer, Elizabeth R.

机构：

[1] Canc Res UK, Ctr Drug Dev, London, England

[2] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England

[3] Inst Canc Res, London, England

[4] Royal Marsden Hosp, London, England

[5] Univ Laval, CHU Quebec, Quebec City, PQ, Canada

[6] Moorfields Eye Hosp, London, England

[7] Imperial Coll London, London, England

[8] Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.2516

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2516

引用

页数：5